Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with <sup>67</sup>Cu.
Where this comes from
- Record sourced from PubMed, PMID 33067341.
- Also identified by DOI 10.2967/jnumed.120.251579 and PMC identifier 8729863.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, <sup>64</sup>Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of <sup>67</sup>Cu-CuSarbisPSMA. <b>Methods:</b> Growth of PSMA-positive xenografts was evaluated after treatment with <sup>67</sup>Cu-CuSarbisPSMA or <sup>177</sup>Lu-LuPSMA imaging and therapy (I&T). <b>Results:</b> At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations. <b>Conclusion:</b><sup>67</sup>Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.
Medical subject headings
- Antigens, Surface
- Copper Radioisotopes
- Glutamate Carboxypeptidase II